KOBAYASHI PHARMACEUTICAL CO.,LTD.
小林製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4967
FY2025 (Dec 2025) · J-GAAP · consolidated Source: filing S100XSXS
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Dec 2025) runs Jan 1, 2025 – Dec 31, 2025.
| Gross margin | 51.1% |
|---|---|
| Operating margin | 9.0% |
| Net margin | 2.2% |
| Return on equity | 1.7%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 1.4% |
| Revenue growth (YoY) | 0.1% |
| EPS (basic) | ¥49.19 |
| EPS growth (YoY) | -63.7% |
| Current ratio | 2.47x |
| Equity ratio | 76.3% |
| Book value / share | ¥2,827.68 |
| Free cash flow | ¥11.6B |